Skip to main content
S 251 110th Congress Senate Health Administrative fees Administrative procedure Administrative remedies Africa (Sub-Saharan) Australia Austria Belgium Business records Canada Civil actions and liability Commerce Congress Congressional reporting requirements Consumer education Consumer protection Damages Denmark Department of Health and Human Services Drug approvals

Pharmaceutical Market Access Act of 2007

Introduced: January 10, 2007 See on congress.gov
This bill died when the 110th Congress ended
It never became law before the 110th Congress (2007–2008) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jan 10, 2007
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Jan 10, 2007
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Pharmaceutical Market Access Act of 2007 - Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary of Health and Human Services to promulgate regulations permitting pharmacists, pharmacies, and wholesalers to import qualifying drugs from certain countries into the United States.

Sets forth registration requirements for exporters.

Requires the Secretary to: (1) educate consumers with regard to the availability of qualifying drugs for import for personal use; (2) inspect the facilities and records of importers and registered exporters to ensure compliance with this Act; and (3) establish a registration fee program to collect an annual fee from registered exporters.

Deems a prescription drug to be misbranded unless the packaging of such drug complies with the requirements for counterfeit-resistant technologies.

Prohibits: (1) failing to register in accordance with this Act; and (2) importing or offering to import a prescription drug in violation of a suspension order.

Declares that selling or importing a patented drug in the United States that was first sold abroad by or under authority of the owner or licensee of the patent is not patent infringement.

Prohibits drug manufacturers from discriminating against a person that engages in the importation of a prescription drug, including by charging higher prices or denying supplies of the drug.

Allows the Secretary to suspend or terminate the registration of an exporter for failing to maintain substantial compliance with all registration conditions.

What's happening now January 10, 2007

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). S. 251: Pharmaceutical Market Access Act of 2007. 110th Congress. Open America. https://openamerica.io/bill/110-S-251/
MLA
"S. 251: Pharmaceutical Market Access Act of 2007." 110th Congress, 2026, Open America, https://openamerica.io/bill/110-S-251/.
Bluebook (legal)
S. 251, 110th Cong. (2026), https://openamerica.io/bill/110-S-251/.
Markdown link
[S. 251: Pharmaceutical Market Access Act of 2007](https://openamerica.io/bill/110-S-251/)
Report a problem